Oxytocin Phase 2 Trial Registered for Drug-Induced Respiratory Compromise

A new clinical trial involving oxytocin was registered on October 29, 2026. The study, titled "Oxytocin for Respiratory Compromise and Hypoventilation Induced by Drugs," is listed under identifier NCT07902752. It is designated as a Phase 2 trial. According to the registry entry, the trial status is currently "not yet recruiting." No participants have been enrolled at this stage, and no results have been posted. The trial record does not provide additional details on design, outcomes, or expected timelines beyond its registration status. Oxytocin is an approved compound, and this trial represents a new investigational use under study. As with any trial update, the information available at this stage is limited to the registration details themselves. No efficacy or safety outcomes can be inferred from a not-yet-recruiting status. Readers interested in tracking this trial should refer to the official registry listing for updates as the study progresses toward recruitment and beyond. For more background on oxytocin, including its approved uses and general pharmacology, see the compound overview.